LAUSR

John Cleland is honoured to have been invited to be an International Associate Editor for the World’s leading journal on Cardiovascular Disease; the European Heart Journal. As a junior research fellow, he published his first paper in EHJ in 1985 (one of the very first randomized trials of ACE inhibitors); since when he has published 90 more papers! He has seen the reputation and impact of the journal rise from very modest beginnings to its current outstanding position. John’s major research interest has always been on heart failure, initially under the supervision of Professor Henry Dargie in Glasgow and then Celia Oakley at the Hammersmith Hospital in London. He was first appointed as Professor of Cardiology at the University of Hull (England) where he spent 14 years and achieved some of his greatest career successes in cardiac resynchronization therapy (CARE-HF trial), telehealth (TEN-HMS trial), and HFpEF (PEP-CHF trial). Currently, John Cleland is the Director of the Robertson Centre for Biostatistics and Clinical Trials in Glasgow but also holds a part-time position at Imperial College, London and an Honorary position at the University of Hull. His current interests include the development of a Heart Failure Investigators Research Network that can benefit from the generous funding for clinical research in the UK and the development of investigator-led clinical trials investigating morbidity and mortality and the creation of a ‘population-laboratory’ to investigate trends and disease pathways in the West of Scotland ( 100 million person-years of follow-up) that will act as a spring board for the development of trials to prevent heart failure. As each year goes by, ‘I feel that the pace of research is accelerating. When I look back, I am astonished at what our basic and clinical research communities have achieved. When I look forward, I am even more excited’. CardioPulse 3279